Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer.

× No keyword cloud information.

7 in total

Review 1. A history of prostate cancer treatment.

Authors: Samuel R Denmeade; John T Isaacs
Journal: Nat Rev Cancer Date: 2002-05 Impact factor: 60.716

2. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.

Authors: Samuel R Denmeade; Annastasiah M Mhaka; D Marc Rosen; W Nathaniel Brennen; Susan Dalrymple; Ingrid Dach; Claus Olesen; Bora Gurel; Angelo M Demarzo; George Wilding; Michael A Carducci; Craig A Dionne; Jesper V Møller; Poul Nissen; S Brøgger Christensen; John T Isaacs
Journal: Sci Transl Med Date: 2012-06-27 Impact factor: 17.956

3. Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen.

Authors: Bakheet Elsadek; Ralph Graeser; André Warnecke; Clemens Unger; Tahia Saleem; Nagla El-Melegy; Hafez Madkor; Felix Kratz
Journal: ACS Med Chem Lett Date: 2010-05-26 Impact factor: 4.345

4. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.

Authors: Simon A Williams; Rosemina F Merchant; Elizabeth Garrett-Mayer; John T Isaacs; J Thomas Buckley; Samuel R Denmeade
Journal: J Natl Cancer Inst Date: 2007-03-07 Impact factor: 13.506

5. Screening for new peptide substrates for the development of albumin binding anticancer pro-drugs that are cleaved by prostate-specific antigen (PSA) to improve the anti tumor efficacy.

Authors: Bakheet E M Elsadek; Mohammed H Hassan
Journal: Biochem Biophys Rep Date: 2021-03-02

6. The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.

Authors: Yasuhiro Tsume; Blanca Borras Bermejo; Gordon L Amidon
Journal: Pharmaceuticals (Basel) Date: 2014-01-27

7. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.

Authors: D Mahalingam; G Wilding; S Denmeade; J Sarantopoulas; D Cosgrove; J Cetnar; N Azad; J Bruce; M Kurman; V E Allgood; M Carducci
Journal: Br J Cancer Date: 2016-04-26 Impact factor: 7.640

7 in total